Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets
June 27, 2018 08:00 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing to appeal...
Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
March 12, 2018 08:00 ET
|
Anthera Pharmaceuticals, Inc.
Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”)Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”)Further development...
Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference
March 07, 2018 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria
March 06, 2018 14:45 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that Anthera has received formal notice from The NASDAQ Stock Market LLC (“Nasdaq”)...
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results
March 05, 2018 16:05 ET
|
Anthera Pharmaceuticals, Inc.
RESULT study reported positive interim futility analyses and completion of dosing, with top line data expected in March 2018Completed private placement for net proceeds of $13.3 million...
Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orphan Drug Day
February 08, 2018 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
February 05, 2018 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) is pleased to announce that the final patient has completed the last visit in the primary treatment...
Anthera Receives Positive Nasdaq Listing Determination
January 25, 2018 16:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq Hearings Panel...
Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter
January 22, 2018 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for the...
Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
January 09, 2018 17:15 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has completed the second closing of the private placement of its equity...